Last reviewed · How we verify
Invokana (CANAGLIFLOZIN)
Invokana (generic name: CANAGLIFLOZIN) is a Sodium-Glucose Cotransporter 2 Inhibitor Small molecule drug developed by Johnson & Johnson. It is currently FDA-approved (first approved 2013) for Chronic kidney disease (CKD) associated with type 2 diabetes (T2D), Diabetes mellitus type 2.
Invokana works by blocking the SGLT2 protein in the kidneys to reduce glucose reabsorption.
Invokana (Canagliflozin) is a small molecule Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor developed by Janssen Pharmaceuticals. It works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine. Invokana is approved to treat chronic kidney disease associated with type 2 diabetes and diabetes mellitus type 2. It remains a patented product with no generic manufacturers. Key safety considerations include increased risk of amputations, ketoacidosis, and hypotension.
At a glance
| Generic name | CANAGLIFLOZIN |
|---|---|
| Sponsor | Johnson & Johnson |
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor |
| Target | Sodium/glucose cotransporter 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2013 |
| Annual revenue | 800 |
Mechanism of action
CanagliflozinSodium-glucose co-transporter (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion (UGE).. MetforminMetformin is an antihyperglycemic agent which improves glucose tolerance in patients with type diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
Approved indications
- Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
- Diabetes mellitus type 2
Common side effects
- Female genital mycotic infections
- Urinary tract infections
- Increased urination
- Thirst
- Constipation
- Nausea
- Vulvovaginal pruritus
- Fatigue
- Abdominal pain
- Loss of strength or energy
- Cystitis
- Kidney infection
Drug interactions
- P-glycoprotein Substrates
- fosphenytoin
- phenobarbital
- phenytoin
- primidone
- rifampicin
- ritonavir
Key clinical trials
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- Safety and Efficacy of Canagliflozin in Advanced CKD (PHASE4)
- Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis (PHASE2)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment (PHASE1)
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Invokana CI brief — competitive landscape report
- Invokana updates RSS · CI watch RSS
- Johnson & Johnson portfolio CI
Frequently asked questions about Invokana
What is Invokana?
How does Invokana work?
What is Invokana used for?
Who makes Invokana?
What is the generic name of Invokana?
What drug class is Invokana in?
When was Invokana approved?
What development phase is Invokana in?
What are the side effects of Invokana?
What is Invokana's annual revenue?
What does Invokana target?
Related
- Drug class: All Sodium-Glucose Cotransporter 2 Inhibitor drugs
- Target: All drugs targeting Sodium/glucose cotransporter 2
- Manufacturer: Johnson & Johnson — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
- Indication: Drugs for Diabetes mellitus type 2
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing